Active Movers in Hot Line: Verizon Communications (NYSE:VZ), Akers Biosciences (NASDAQ:AKER)

Verizon Communications Inc. (NYSE:VZ) [Trend Analysis] knocking active thrust in leading trading session, shares an advance of 1.22% to 52.91 with around 13.37 Million shares have changed hands in this session. Verizon (VZ) has put up four phones accessible for free without trade-in requirements, save for a $20 device activation fee. The free phones being offered include the Moto Z Play Droid, a Verizon exclusive that supports Motorola’s modular-ish Moto Mods; Samsung Galaxy J3 V, a mid-range reported early this year; and the LG K8 V and Stylo 2.

The Moto Z Play Droid rocks a 5.5-inch Super AMOLED display with a resolution of 1,920 x 1,080. Under the hood is an 2 GHz octa-core Qualcomm Snapdragon 625 processor and an Adreno 506 GPU. On the back is a 16-megapixel shooter capable of shooting 4K video at 30 fps, while on the front is 5-megapixel shooter with 1080p video recording support. The stock is going forward its fifty-two week low with 24.74% and lagging behind from its 52-week high price with -5.09%.

Similar, the positive performance for the quarter recorded as 3.25% and for the year was 18.50%, while the YTD performance remained at 18.19%. VZ has Average True Range for 14 days of 0.79.

Shares of Akers Biosciences, Inc. (NASDAQ:AKER) [Trend Analysis] swings enthusiastically in regular trading session, it a decrease of -2.94% to close at $1.65. Akers Biosciences, Inc. (NASDAQ:AKER) has signed a three-year contract with the Greater New York Hospital Association (GNYHA) to introduce the Company’s flagship rapid tests for heparin-induced thrombocytopenia across GNYHA’s network of over 300 member hospitals.

Akers Bio believes its rapid tests have the capacity to provide dramatic cost savings for hospitals when compared to traditional testing methodologies for detecting HIT. The Company estimates that a typical hospital can save $0.5 – $1 million per annum in testing, pharmacy, and clinical monitoring costs.

John J. Gormally, Chief Executive Officer of Akers Bio, commented: “Akers Bio is delighted to have signed a three-year contract with GNYHA, one of the premier group purchasing organizations in the United States healthcare sector. Their membership includes a diverse listing of prominent and large integrated delivery networks (IDNs) and hospitals. Enhanced access to GNYHA’s network has the potential to dramatically increase domestic sales of our flagship product. Moving forward to saw long-term intention, the experts calculate Return on Investment of -142.60%. The stock is going forward its fifty-two week low with 52.78% and lagging behind from its 52-week high price with -55.41%. AKER last month stock price volatility remained 12.33%.


About Aaron Smithies

Aaron Smithies has a wide look on current monetary and financial events. He is an editor and a writer. His views; At Streetwise Report, we think the best opportunities arise from a complete understanding of all investing disciplines in order to identify the most attractive stocks at any given time. Interests: Biotech, Finical markets, Dividend stock ideas & income, Energy stocks, Consumer goods stocks

Leave a Reply

Your email address will not be published. Required fields are marked *